Drugs / Sacubitril / Valsartan
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04458285 | Jan → Dec 2020 | heart failure | Guangdong Provincial People's Hospital | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-07-07 | Novartis Pharmaceuticals | Novartis will appeal to U.S. Court of Appeals to uphold validity of Entresto® combination patent; maintains 2023 guidance and mid-term outlook novartis.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sacubitril / Valsartan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04458285 ↗ |
| Known as | Entresto | “Sacubitril / Valsartan Oral Tablet [Entresto]” NCT04458285 ↗ |
| Route | Oral | “Sacubitril / Valsartan Oral Tablet [Entresto]” NCT04458285 ↗ |